Correlation between Protective Immunity to \(\alpha\)-Synuclein Aggregates, Oxidative Stress and Inflammation

Marina A. Gruden\textsuperscript{a}  Kiran Yanamandra\textsuperscript{d}  Valery G. Kucheryanu\textsuperscript{b}  
Olga R. Bocharova\textsuperscript{c}  Vladimir V. Sherstnev\textsuperscript{a}  Ludmilla A. Morozova-Roche\textsuperscript{d}  
Robert D.E. Sewell\textsuperscript{e}

\textsuperscript{a}P.K. Anokhin Institute of Normal Physiology, \textsuperscript{b}Institute of General Pathology and Pathophysiology and \textsuperscript{c}N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia; \textsuperscript{d}Department of Medical Biochemistry and Biophysics, Umeå University, Umeå, Sweden; \textsuperscript{e}Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK

Key Words  
Parkinson’s disease \cdot \alpha\)-Synuclein oligomers \cdot Autoantibodies \cdot Cytokines \cdot Oxidative stress

Abstract  
Objective: Protein aggregation leading to central amyloid deposition is implicated in Parkinson’s disease (PD). During disease progression, inflammation and oxidative stress may well invoke humoral immunity against pathological aggregates of PD-associated \(\alpha\)-synuclein. The aim was to investigate any possible concurrence between autoimmune responses to \(\alpha\)-synuclein monomers, oligomers or fibrils with oxidative stress and inflammation. Methods: The formation of \(\alpha\)-synuclein amyloid species was assessed by thioflavin-T assay and atomic force microscopy was employed to confirm their morphology. Serum autoantibody titers to \(\alpha\)-synuclein conformations were determined by ELISA. Enzyme activity and concentrations of oxidative stress/inflammatory indicators were evaluated by enzyme and ELISA protocols. Results: In PD patient sera, a differential increase in autoantibody titers to \(\alpha\)-synuclein monomers, toxic oligomers or fibrils was associated with boosted levels of the pro-inflammatory cytokine interleukin-6 and tumour necrosis factor-\(\alpha\), but a decrease in interferon-\(\gamma\) concentration. In addition, levels of malondialdehyde were elevated whilst those of glutathione were reduced along with decrements in the activity of the antioxidants: superoxide dismutase, catalase and glutathione transferase. Conclusions: It is hypothesized that the generation of \(\alpha\)-synuclein amyloid aggregates allied with oxidative stress and inflammatory reactions may invoke humoral immunity protecting against dopaminergic neuronal death. Hence, humoral immunity is a common integrative factor throughout PD progression which is directed towards prevention of further neurodegeneration, so potential treatment strategies should attempt to maintain PD patient immune status.

Introduction  
The increased levels of monomeric and oligomeric species of \(\alpha\)-synuclein may be promising bioindicators of the pathological conditions occurring in Parkinson’s disease (PD) [1]. It has also been demonstrated that prefibrillar aggregates of \(\alpha\)-synuclein, similar to other amyloid species, are candidates as generic toxins [2]. During PD
progression, there is a complex of interrelated pathological conditions involving humoral and cellular immunity [3–5] arising from oxidative stress and inflammation [6–8] which are forerunners of the protein misfolding cascade [9]. Oxidative stress may not only result in neuroinflammation, but also in the formation of poorly degraded proteins stemming from the actions of reactive oxygen species (ROS) or nitrogen species which favour the misfolding of α-synuclein [7]. On the other hand, dopaminergic neurodegeneration may arise partially from the modulation of glial function as a result of elevated soluble or insoluble α-synuclein released from affected neurons in Lewy bodies. α-Synuclein is nitrated during oxidative stress, and in its aggregated form, it incites microglial inflammation [10]. These processes, during the initial degenerative stages of parkinsonism, may possibly instigate compensatory immunological consequences [11]. Raised levels of oligomeric forms of α-synuclein have been described in the plasma of PD patients [12]. Subsequently, we have focused on autoimmune reactions towards aberrant antigens involved in PD which could serve as sensitive indicators of subtle shifts in biochemical processes occurring during the initial stages of the disease pathogenesis. Accordingly, elevated concentrations of toxic misfolded protein species may potentially modify natural autoimmunity in humans [3–5, 13–15], suggesting a protective role of autoimmunity in PD [3]. In this study, we undertake endeavours to ascertain possible interrelationships between autoimmune responses to biomarkers such as monomeric, toxic oligomeric or fibrillar forms of α-synuclein and the main indicators of oxidative stress and inflammation in PD.

**Methods**

**Human Subjects**

PD patients (n = 38) of either gender (22 males and 16 females) within the age range 43–78 years (mean 62.7 ± 2.3) were recruited from the Russian Research Center of Neurology of the Russian Academy of Medical Sciences. Patients underwent neurological examination and were diagnosed with PD and classified according to their disease severity by the Unified PD Rating Scale (UPDRS) [16]. Patient scores ranged from 1 to 4, the majority being grade 2 on the Hoehn and Yahr scale [17]. Both patient and control group demographics are shown in Table 1. The interval between diagnosis was ≤5 years. Eighteen PD patients presented primarily with tremor accompanied by rigidity, while 19 possessed predominantly rigidity along with tremor and 1 individual was diagnosed with the akinetic rigid form of the disease (i.e. all patients were in the off phase of the on-off cycle) (table 2). All patients were treated with dopaminergic-based antiparkinsonian therapy including the L-DOPA dopamine (DA) precursor agents L-Dopa + carbidopa (Sinemet CR® or Nacom®) or L-Dopa + benserazide (Madopar®), the non-ergot D2/D3 agonists Piribedil (Pronoran®) or pramipexole (Miropex®). The mean group dose for L-Dopa over 4.2 ± 0.7 treatment years was 411.5 ± 134.6 g/patient.

Patients with concomitant neurological or psychiatric diseases, cancer and other severe diseases were excluded. Healthy age-matched control individuals (n = 26) were selected and the exclusion criteria were identical to those for PD patients. All patients and control subjects gave their informed consent to participate in the study, which was conducted in accord with the provisions of the World Medical Association Declaration of Helsinki (2000).

**Source and Preparation of Samples**

α-Synuclein was purchased from Millipore, USA. Blood samples (5 ml) from all patients and controls were collected without additives. After 1 h of coagulation, samples were centrifuged for 15 min at 3,500 g (4°C). The sera were collected, aliquoted into Eppendorf tubes, frozen immediately and stored at –80°C, before being defrosted and subjected to a range of biochemical analyses.

**Production of α-Synuclein Amyloidogenic Species**

In order to produce cytotoxic amyloid oligomers [4, 18], α-synuclein (3 mg/ml) was incubated in 10 mM Na2HPO4 at pH 7.4 and 37°C with continuous agitation at 300 rpm for 7 days and fibrils for 14 days.

**ELISA of Serum Antibodies to Monomers, Oligomers and Fibrils of α-Synuclein**

The titers of serum antibodies to α-synuclein monomers oligomers and fibrils were determined by ELISA [4, 19] in 96-well

<table>
<thead>
<tr>
<th>Table 1. Group characteristics of the study population</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group characteristics</strong></td>
</tr>
<tr>
<td>Age, years</td>
</tr>
<tr>
<td>Male:female</td>
</tr>
<tr>
<td>Age at onset of PD, years</td>
</tr>
<tr>
<td>Duration of PD, years</td>
</tr>
<tr>
<td>UPDRS motor score</td>
</tr>
<tr>
<td>Hoehn and Yahr stage</td>
</tr>
</tbody>
</table>

Data of quantitative variables are expressed as group mean ± SEM.

<table>
<thead>
<tr>
<th>Table 2. Clinical analysis of PD patients by UPDRS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical components of UPDRS</strong></td>
</tr>
<tr>
<td>Impairment of daily activity</td>
</tr>
<tr>
<td>Motor activity</td>
</tr>
<tr>
<td>Tremor</td>
</tr>
<tr>
<td>Rigidity</td>
</tr>
<tr>
<td>Bradykinesia</td>
</tr>
</tbody>
</table>

α-Synuclein Immunoprotection in Parkinson’s Disease
freshly cleaved mica, washed with MiliQ water (3 × 100 μl) and dried overnight at room temperature. The distribution of dimensions of the amyloid species was measured in atomic force microscopy (AFM) cross sections.

**Thioflavin-T Amyloid Binding Assay**

The formation of amyloid oligomers was assessed using thioflavin-T dye binding assay, employing a modification of the method described previously [26]. The fluorescence measurements were performed on a Jasco FP-6500 spectrofluorometer (Jasco, Japan). The dye was excited at 440 nm and emission spectra were recorded between 450–550 nm, setting the excitation and emission slits at 3 nm.

**Statistical Analysis**

Comparison between groups was carried out non-parametrically using the Mann-Whitney test and the 2-tailed Student t test for unequal variance. Spearman’s coefficient was used to evaluate the correlation between two variables.

**Results**

**Characterization of α-Synuclein Oligomeric and Fibrillar Species**

Oligomeric species of α-synuclein were produced at pH 7.4 with agitation and characterized by the thioflavin-T binding assay and then AFM analysis prior to ELISA, which was particularly important since amyloid species display an inherent diversity of structures dependent on solution conditions. The samples containing oligomers were collected at the end of the lag phase (7 days), at which time a detectable fluorescence increase was observed, as shown in figure 1d, indicative of cross-β-sheet formation. The oligomers were characterized by a round-shaped morphology assessed by AFM imaging (fig. 1a). The distribution of oligomeric particle heights measured in AFM cross sections is shown in figure 1b. They were represented by a wide range of species with heights from 1.2 to 3.9 nm. Their maximal population was centered around species of 8–10 nm in height measured by AFM cross-section analysis (fig. 1c).
Autoimmune Responses to α-Synuclein Monomers, Oligomers and Fibrils in PD Patients

Antibodies to monomers, oligomers and fibrils of α-synuclein were subjected to immune analysis in the sera of PD sufferers (≤5 years duration) versus age-matched control subjects. Control and PD serum IgG representative titration curves towards 3 types of α-synuclein states as the antigens have been reported previously by these laboratories [4]. The comparative results of ELISA analysis of immune-reactivity to α-synuclein monomers and oligomers in the blood sera of patients and controls are presented in figure 2. These observations demonstrate that in healthy individuals the immune responses towards monomeric α-synuclein were at the titer cut-off level for ELISA, displaying a very narrow distribution of titers. In contrast, in early PD patients there was a significant increase in IgG reactivity towards α-synuclein monomers (p < 0.0001). There was a wider range of immune responses in this group than in controls with 72% of patients displaying high immune reactivity towards this α-synuclein species. It is important to note that 3 individuals displayed particularly high responses, with up to a 25-fold enhancement in the IgG α-synuclein reactivity as estimated by their titers. A significant (p < 0.05) 17-fold increase in autoimmune reactivity towards α-synuclein monomers compared to controls was observed and, as might be predicted, the variability of this response was greater than in the controls. Titers of autoantibodies to oligomeric species of α-synuclein in approximately 50% of the patient sera were 4-fold higher than the control group. A doubling of titer values to fibrillar α-synuclein species was seen in only 17% of patients with respect to controls, but there was no significance (p > 0.05) to this observation and antibody titers to this protein aggregate remained generally low throughout, so the data was not shown.

Overall, it is clear that all PD patients displayed elevated levels of serum autoantibodies to α-synuclein biochemical markers up to 5 years after disease diagnosis. Moreover, there was no correlation between the autoimmune reactivity to any of the biomarkers with respect to...
age or gender (p = 0.1 which is above p = 0.05 set as the significance level) (data not shown).

**Indicators of Oxidative/Antioxidative Processes (Oxidative Stress) in PD Patients**

The blood concentration of malondialdehyde, as a marker of oxidative stress, was 58.1% higher whilst glutathione decreased (–17.6%) in the entire PD patient group when compared to the age-matched controls (table 3). There was also a reduction of antioxidant activity as indicated by decrements in superoxide dismutase (–22.6%), catalase (–4.6%), and glutathione transferase (–14.3%) in PD blood. These findings could be viewed as evidence of a predominance of oxidative over antioxidant processes in the current PD conditions.

**Serum Cytokine Content in PD Patients**

In comparison to controls, all PD patients disclosed boosted levels of the pro-inflammatory cytokines IL-6 (+444.4%) and TNF-α (+153.3%). In contrast, the anti-inflammatory cytokine INF-γ was decreased by 99.8% (table 4). Taken together, these data suggest that there was a general activation of inflammatory mechanisms in the PD patients studied.

**Discussion**

Autoantibodies with specificity to self-antigens including amyloidogenic proteins have been associated with a broad diversity of neurological diseases [4, 14, 15, 27–29]. It is important to note that amyloid-reactive IgGs are naturally present in the blood sera of healthy individuals, recognizing the common conformational epitope of amyloid fibrils, regardless of their protein composition [30, 31]. It should also be recognized that more than 99% of monomeric α-synuclein in human blood is present in peripheral blood cells with the remainder being in plasma [32]. In this study, serum was employed as the sample body fluid, thus minimizing any erythrocyte-derived α-synuclein contaminant level in the samples. In addition, comparison of age-matched control samples with PD samples would tend to negate the α-synuclein background. We observed a substantial rise in antibody reactivity against α-synuclein monomers in PD sera and this effect was considerably larger than the increase in antibodies against α-synuclein oligomers (fig. 2). Since amyloid formation is a concentration-dependent process, any increase in α-synuclein production or a disbalance in protein metabolism is likely to be an amyloid-prone factor. Therefore, the humoral clearance of monomeric precursor will ultimately constrain the formation of toxic oligomeric species. It has also been shown that overexpression of α-synuclein during the presymptomatic stage of PD is implicated in early changes in synaptic DA release and synaptic dysfunction, triggering disease progression [33]. On the other hand, the most pathogenic oligomeric species of α-synuclein are highly heterogeneous, as shown in the distribution of their sizes in figure 1b, and they are transient in nature. They populate the pathway to fibril formation and can undergo rapid oligomeric inter-conversion or progress to generate larger fibrillar structures. We have measured the immunoreactivity to the whole ensemble of amyloid oligomers and the possibility cannot be excluded that autoimmunity is able to differentiate between pathogenic species and bystanders. Taken together, these facts further emphasize the significance of monomer clearance by humoral immunity as a protective measure against cellular toxicity and degeneration.

We wished to gain an additional insight into any congruence in relation to inflammation, oxidative stress and humoral immunity towards disease-linked protein misfolding in PD. Hence, we analyzed the autoantibodies to native and amyloidogenic species of α-synuclein simultaneous in patient sera as PD biomarkers along with the activity of antioxidant enzymes, malondialdehyde con-
centation and cytokine levels as significant oxidative stress and inflammatory indicators [34]. In normal physiological conditions, α-synuclein exists intrinsically as an unfolded protein, but during altered conditions in vitro and in vivo, it may self-assemble to form ordered fibrillar aggregates [35] characterized by a cross-β-sheet structure similar to the aggregates found in Lewy bodies [36]. It is interesting that the initial phase of the α-synuclein aggregation process is thought to involve the formation of oligomeric species which possess a much higher degree of cytotoxicity than the mature fibrils into which they develop [1, 4, 37]. How α-synuclein species cause neurodegeneration is currently unknown, but increased expression of this protein is associated with elevated susceptibility of cells to oxidative stress, DA toxicity and apoptosis [38]. We have found that during the early stages of the disease, the immune clearance system targets not only the amyloid forms of disease-associated amyloid-β peptide [39], but also lysozyme, which is not related to AD pathology [4]. More recently, a linked triad between olfactory impairment, autoimmunity and neurodegenerative dis-

eases like PD has been described [40]. Moreover, we have shown that processes of α-synuclein misfolding and the appearance of toxic aggregates may invoke humoral immunity in the pathological gambit causing dopaminergic neuronal death in PD [4, 15]. It has also been demonstrated that in terms of cellular immunity in PD, there is a decay of lymphocyte subsets which reflects the influence of inflammatory and oxidative stress reactions [3].

Multi-epitopic autoantibodies against α-synuclein have been detected in 65% of PD patients with an inherited mode of the disease [29]. Moreover, during mice immunization by α-synuclein, in those animals which produced high-affinity antibodies, there was also a decreased accumulation of aggregated α-synuclein in neuronal cell bodies and synapses that were associated with reduced neurodegeneration. Furthermore, antibodies produced by immunized mice recognized abnormal α-synuclein associated with neuronal membranes and promoted the degradation of α-synuclein aggregates, probably via lysosomal pathways. Similar effects were observed with an exogenously applied FITC-tagged α-synuclein antibody [41]. There is a biphasic profile of idiotypic antibody generation to disease-linked proteins and it has also been found that constituents of the classical or antibody-triggered complement cascade occur in Lewy bodies [42]. This evidence substantiates the finding that pathological conditions in PD engage central humoral immunity mechanisms [43].

Thus, in the brain tissue of PD patients, there were significant levels of immunoglobulin G which bound to DA neurons in a concentrated distribution at neuronal surfaces or on Lewy bodies co-localized with α-synuclein [43]. Moreover, initiation of humoral immunity in early onset PD may also be concomitant with the instigation of inflammatory processes which play a fundamental role in the pathogenesis of parkinsonism [44].

<table>
<thead>
<tr>
<th>Cytokines</th>
<th>Controls (pg/ml (mean ± SEM)</th>
<th>PD patients (pg/ml (mean ± SEM)</th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-6</td>
<td>7.2 ± 1.2</td>
<td>39.2 ± 3.0*</td>
<td>+444.4</td>
</tr>
<tr>
<td>TNF-α</td>
<td>1.5 ± 0.7</td>
<td>3.8 ± 1.8*</td>
<td>+153.3</td>
</tr>
<tr>
<td>INF-γ</td>
<td>12.5 ± 2.8</td>
<td>0.09 ± 0.04*</td>
<td>-99.8</td>
</tr>
</tbody>
</table>

* p < 0.05, difference from control values.
It has become increasingly evident that inflammatory and oxidative stress processes play prominent roles in amyloid-related neurodegenerative diseases in general, including Alzheimer’s and prion diseases [45–47]. These processes are sustained mainly by activated microglia and astrocytes, which in response to the pathogenic event, over-secrete bioactive molecules. Thus, amyloidogenic peptides and proteins such as amyloid-β fragments and their amyloid species as well as prions activate microglia and astrocytes inducing secretion of a specific range of cytokines and chemokines (IL-1, IL-6, IL-12, TNF-α and others) in addition to ROS [48, 49]. In both Alzheimer’s and prion diseases, amyloid deposits cause recruitment of proliferating astrocytes and phagocytic microglia. These activated cells may well contribute to the clearance of potentially toxic species, though uncontrollable glial activation may actually exacerbate neuronal damage via prolonged release of inflammatory cytokines, ROS and other diffusible factors [47, 50, 51]. In PD, during these conditions, release of DA may also activate microglia to generate pro-inflammatory cytokines (IL-6 and TNF-α measured peripherally) and a decline in INF-γ content [52, 53]. Our results have at least demonstrated parallel phenomena which would concur with the literature in relation to the generating of α-synuclein aggregate antibody in parkinsonism. It might be hypothesized that there is a protective role for idiotypic autoantibodies to toxic oligomeric species of α-synuclein with the purpose of abolishing the toxic effects of aggregates towards dopaminergic cells in the substantia nigra and other brain regions pertinent to pathology.

Furthermore, oxidative stress has been implicated in the pathogenesis of PD as a result of its role in the cascade of biochemical changes that lead to dopaminergic neuronal death [54]. Graham [55] reported that DA can autoxidize at normal physiological pH to form toxic ROS such as hydroxyl radicals, superoxide anions and DA-quinone species. These ROS are capable of oxidizing DNA, proteins and lipids to modify their biofunctions, for instance, by boosting membrane permeability, thereby intensifying any cell damage [6, 9]. Subsequently, ROS may form covalent adducts with α-synuclein to inhibit the generation of fibrils from oligomeric species, thereby increasing toxicity [56]. This oxidative burden, under normal conditions, is kept in check by antioxidant systems [58]. In both PD and other amyloid-related neurodegenerative diseases, oxidative stress and pro-inflammatory cytokine levels in PD as well as in other amyloid-related neurodegenerative diseases is not merely circumstantial, but reflects complex interconnected pathological processes causing disease progression. The differential production of monomer and amyloid specific antibodies appears to reflect the continuum from non-toxic to toxic species and this might be exploited as a diagnostic tool for neurodegenerative states. Moreover, humoral immunity is a common integrative factor throughout PD progression which is directed towards prevention of further neurodegeneration, hence potential treatment strategies should attempt to maintain PD patient immune status.

**Acknowledgements**

We wish to thank Dr. Vsevolod V. Polyschuk from the Russian Research Center of Neurology, RAMS, Moscow, for access to patients, and Elena I. Elistratova for technical assistance provided throughout the study. L.A.M.R. thanks the Swedish Medical Research Council and Insamlingsstiftelsen, Umeå, for financial support.
References


alpha-Synuclein Immunoprotection in Parkinson's Disease

Neuroimmunomodulation 2012;19:334–342

341


